Ganolucidic acid E

Ganolucidic acid E
Product Name Ganolucidic acid E
CAS No.: 114567-50-9
Catalog No.: CFN95536
Molecular Formula: C30H44O5
Molecular Weight: 484.7 g/mol
Purity: >=98%
Type of Compound: Triterpenoids
Physical Desc.: Powder
Source: The fruit body of Ganoderma lucidum
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $318/5mg
Ganolucidic acid E inhibits the growth of three types of human cancer cells: Caco-2, HepG2 and HeLa cells.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • J Korean Med Ophthalmol Otolaryngol Dermatol2023, 36(1):21-39.
  • Front Pharmacol.2021, 12:615157.
  • VNU Journal of Science: Med.& Pharm. Sci.2022, 38(2):2588-1132.
  • Cell Physiol Biochem.2019, 52(6):1255-1266
  • Food Chem.2022, 378:131975.
  • Br J Pharmacol.2020, 10.1111
  • Molecules.2019, 25(1):E103
  • Analytical Letters 2021, 54(4).
  • Emirates Journal of Food and Agriculture.2022, 34(6): 528-536.
  • Braz J Biol.2023, 82:e266573.
  • New compound 21

    Catalog No: CFN95560
    CAS No: N/A
    Price: $413/5mg
    Ganoderic acid Y

    Catalog No: CFN90294
    CAS No: 86377-52-8
    Price: Inquiry(manager@chemfaces.com)
    Ganoderic acid SZ

    Catalog No: CFN97426
    CAS No: 865543-37-9
    Price: Inquiry(manager@chemfaces.com)
    Ganoderic acid S

    Catalog No: CFN99066
    CAS No: 104759-35-5
    Price: $568/5mg
    Ganoderic acid TN

    Catalog No: CFN90298
    CAS No: 112430-64-5
    Price: $318/5mg
    Ganoderic acid X

    Catalog No: CFN92996
    CAS No: 86377-53-9
    Price: $463/5mg
    Ganoderic acid Jb

    Catalog No: CFN92997
    CAS No: 112430-68-9
    Price: Inquiry(manager@chemfaces.com)
    Ganoderic acid TR

    Catalog No: CFN92235
    CAS No: 862893-75-2
    Price: $368/5mg
    Ganoderic acid T-Q

    Catalog No: CFN92237
    CAS No: 112430-66-7
    Price: $413/5 mg
    Coccinic acid

    Catalog No: CFN99083
    CAS No: 107783-45-9
    Price: Inquiry(manager@chemfaces.com)
    Phytother Res . 2015 Nov;29(11):1744-1752.
    Distinct Responses of Cytotoxic Ganoderma lucidum Triterpenoids in Human Carcinoma Cells[Pubmed: 26292672]
    The medicinal mushroom Ganoderma lucidum is well recognized for its effective cancer-preventative and therapeutic properties, while specific components responsible for these anticancer effects are not well studied. Six triterpenoids that are Ganolucidic acid E, lucidumol A, ganodermanontriol, 7-oxo-ganoderic acid Z, 15-hydroxy-ganoderic acid S, and ganoderic acid DM were isolated and identified from an extract of the mushroom. All compounds reduced cell growth in three human carcinoma cells (Caco-2, HepG2, and HeLa cells) dose dependently with LC50s from 20.87 to 84.36 μM. Moreover, the six compounds induced apoptosis in HeLa cells with a maximum increase (22%) of sub-G1 accumulations and 43.03% apoptotic cells in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (15-hydroxy-ganoderic acid S treatment). Apoptosis was further confirmed by annexin-V staining. Four of the compounds also caused apoptosis in Caco-2 cells with maximum 9.5% increase of sub-G1 accumulations (7-oxo-ganoderic acid Z treatment) and maximum 29.84% apoptotic cells in TUNEL assay (ganoderic acid DM treatment). Contrarily, none of the compounds induced apoptosis in HepG2 cells. The different responses of the three cell lines following these treatments indicated that the bioactive properties of these compounds may vary from cells of different sites of origin and are likely acting under diverse regulatory mechanisms.
    Phytother Res . 2015 Nov;29(11):1744-1752.
    Distinct Responses of Cytotoxic Ganoderma lucidum Triterpenoids in Human Carcinoma Cells[Pubmed: 26292672]
    The medicinal mushroom Ganoderma lucidum is well recognized for its effective cancer-preventative and therapeutic properties, while specific components responsible for these anticancer effects are not well studied. Six triterpenoids that are Ganolucidic acid E, lucidumol A, ganodermanontriol, 7-oxo-ganoderic acid Z, 15-hydroxy-ganoderic acid S, and ganoderic acid DM were isolated and identified from an extract of the mushroom. All compounds reduced cell growth in three human carcinoma cells (Caco-2, HepG2, and HeLa cells) dose dependently with LC50s from 20.87 to 84.36 μM. Moreover, the six compounds induced apoptosis in HeLa cells with a maximum increase (22%) of sub-G1 accumulations and 43.03% apoptotic cells in terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (15-hydroxy-ganoderic acid S treatment). Apoptosis was further confirmed by annexin-V staining. Four of the compounds also caused apoptosis in Caco-2 cells with maximum 9.5% increase of sub-G1 accumulations (7-oxo-ganoderic acid Z treatment) and maximum 29.84% apoptotic cells in TUNEL assay (ganoderic acid DM treatment). Contrarily, none of the compounds induced apoptosis in HepG2 cells. The different responses of the three cell lines following these treatments indicated that the bioactive properties of these compounds may vary from cells of different sites of origin and are likely acting under diverse regulatory mechanisms.
    Carasiphenol C

    Catalog No: CFN95045
    CAS No: 868168-04-1
    Price: $368/5mg
    Tuberosin

    Catalog No: CFN95107
    CAS No: 41347-45-9
    Price: $218/5mg
    5-Hydroxy-7-(4'-hydroxy-3'-methoxyphenyl)-1-phenyl-3-heptanone (DHPA)

    Catalog No: CFN95135
    CAS No: 79559-61-8
    Price: $268/20mg
    Somnifericin

    Catalog No: CFN95280
    CAS No: 173693-57-7
    Price: $318/5mg
    Annphenone

    Catalog No: CFN95426
    CAS No: 61775-18-6
    Price: $318/10mg
    Dehydrodicatechin A

    Catalog No: CFN95451
    CAS No: 36048-23-4
    Price: $318/5mg
    Regaloside I

    Catalog No: CFN95525
    CAS No: 126239-78-9
    Price: $318/5mg
    Methyl ganoderate A

    Catalog No: CFN95550
    CAS No: 105742-78-7
    Price: $413/5mg
    Ephedrannin A

    Catalog No: CFN95579
    CAS No: 82001-39-6
    Price: $318/5mg
    Clinopodic acid E

    Catalog No: CFN95595
    CAS No: 159736-38-6
    Price: $318/5mg